Nick talks to Dr. Berra Yazar-Klosinski, the Chief Science Officer for the Multidisciplinary Association for Psychedelic Studies  (MAPS). Berra talked about the results of MAPS' recent Phase III clinical trials for treating severe PTSD, how these studies are conducted, and what we know about the underlying biology of Post-Traumatic Stress Disorder (PTSD) and the drug MDMA.  Support the showSign up for the free weekly Mind & Matter newsletter:[https://mindandmatter.substack.com/?sort=top]Learn how you can further support the podcast: [https://mindandmatter.substack.com/p/how-to-support-mind-and-matter]Become a Premium Subscriber to access full content library, including full premium episodes:[https://mindandmatter.substack.com/subscribe?utm_source=menu&simple=true&next=https%3A%2F%2Fmindandmatter.substack.com%2F]Try the Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for $50 off:[https://www.lumen.me/shop?fid=8731&utm_source=influencer&utm_medium=influencer&discount=MIND]